Compound details
3-O-beta-D-Galactopyranosylproanthocyanidin A5\'
| Compound ID | CDAMM01527 |
|---|---|
| Common name | 3-O-beta-D-Galactopyranosylproanthocyanidin A5\' | IUPAC name | 5,13-bis(3,4-dihydroxyphenyl)-21-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,12,14-trioxapentacyclo[11.7.1.02,11.03,8.015,20]henicosa-2(11),3(8),9,15,17,19-hexaene-6,9,17,19-tetrol |
| Molecular formula | C36H34O17 |
| Retention time | 2.7 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 739.188 | Theoretical mz | 739.187 |
| Error | 1.11 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 5.7445 |
| Inchi key | JUIIUJBWZYKSEP-UHFFFAOYNA-N |
|---|---|
| Smiles | OC=1C=C(O)C2=C(OC3(OC4=CC(O)=C5C(OC(C6=CC=C(O)C(O)=C6)C(O)C5)=C4C2C3OC7OC(CO)C(O)C(O)C7O)C8=CC=C(O)C(O)=C8)C1 |
| Superclass | Phenylpropanoids and polyketides |
| Class | Flavonoids |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P20151 | KLK2 | Kallikrein 2 | T01908 | SEA |
| P15692 | VEGFA | Vascular endothelial growth factor A | T20761 | SEA |
| P05230 | FGF1 | Acidic fibroblast growth factor | T18639 | SEA |
| P09038 | FGF2 | Basic fibroblast growth factor | T31621 | SEA |
| P01112 | HRAS | Transforming protein p21/H-Ras-1 | T71081 | SEA |
| P60568 | IL2 | Interleukin-2 | T61698 | SEA |
| P49763 | PGF | Placenta growth factor | T70792 | SEA |
| P04746 | AMY2A | Pancreatic alpha-amylase | T86918 | SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| P52209 | PGD | 6-phosphogluconate dehydrogenase | T76497 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T01908 | DI0213 | Innate/adaptive immunodeficiency | [ICD-11: 4A00] | P20151 | KLK2 |
| T20761 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P15692 | VEGFA |
| T20761 | DI0365 | Retinopathy | [ICD-11: 9B71] | P15692 | VEGFA |
| T20761 | DI0430 | Vascular system developmental anomaly | [ICD-11: LA90] | P15692 | VEGFA |
| T18639 | DI0081 | Chronic arterial occlusive disease | [ICD-11: BD4Z] | P05230 | FGF1 |
| T18639 | DI0102 | Coronary atherosclerosis | [ICD-11: BA52] | P05230 | FGF1 |
| T31621 | DI0005 | Acne vulgaris | [ICD-11: ED80] | P09038 | FGF2 |
| T61698 | DI0275 | Multiple sclerosis | [ICD-11: 8A40] | P60568 | IL2 |
| T61698 | DI0361 | Renal cell carcinoma | [ICD-11: 2C90] | P60568 | IL2 |
| T70792 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P49763 | PGF |
| T86918 | DI0110 | Cystic fibrosis | [ICD-11: CA25] | P04746 | AMY2A |
| T86918 | DI0328 | Pancreatic malfunction | [ICD-11: DC30-DC3Z] | P04746 | AMY2A |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |
| T76497 | DI0337 | Pituitary gland disorder | [ICD-11: 5A60-5A61] | P52209 | PGD |